# GPN Vaccines: Research, Canberra, Australia

> GPN Vaccines: GPN Vaccines is a clinical-stage biotechnology company based in Adelaide and Canberra, Australia, founded in 2017. Based in Canberra, Australia.

Source: https://millionrounds.com/startup/gpn-vaccines (Millionrounds; every figure on the page links to its filing or article)

Australia · [Research startup](https://millionrounds.com/companies)

# GPN Vaccines

GPN Vaccines is a clinical-stage biotechnology company based in Adelaide and Canberra, Australia, founded in 2017.

Email

Funding reported Last round: Series B

Research Canberra, Australia

Follow GPN Vaccines and see its new rounds in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Fstartup%2Fgpn-vaccines)

Company summary

- **Founded:** 2017 9 years old
- **Team:** 36 11 to 50 people
- **Funding reported:** 36.1M as listed, currency not stated
- **Last round:** Series B Jun 2024

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for GPN Vaccines has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About GPN Vaccines

GPN Vaccines is a clinical-stage biotechnology company based in Adelaide and Canberra, Australia, founded in 2017.

The company is focused on developing a universal vaccine, Gamma-PN, against *Streptococcus pneumoniae*, which causes serious diseases like pneumonia and meningitis. GPN Vaccines aims to provide robust protection against all serotypes of this pathogen, addressing the limitations of existing vaccines that only cover a subset of strains. The company has successfully completed a Phase 1 study and is moving towards Phase 2 trials to further evaluate the safety and immunogenicity of Gamma-PN. GPN Vaccines has raised approximately $21.5 million in funding, including a significant Series B round in June 2024. Led by CEO Dr. Tim Hirst, the company is dedicated to advancing public health through innovative vaccine solutions, targeting both children and older adults, particularly those aged 70 and over, who are at higher risk for pneumococcal diseases.

## What company datasets say GPN Vaccines raised

Funding, as reported

Reported in all **36.1M** in the source's currency

Rounds **7**

Last round **Series B**

Last round size **11.7M**

Last round date **Jun 2024**

Investors listed **6**

## Founders and team

From GPN Vaccines's own website: 5 on the team.

- **Antiksha Joshi** Director of Quality
- **Malachi Obst** Research Officer
- **Miriam Dodd** Quality Manager
- **Peter Mills** Director of International
- **Shawn Luo** Research Officer

Advisers *MPhil Student*

## On a portfolio page

Investors who name them

- [Shearwater Capital](https://millionrounds.com/fund/shearwater-capital)

Each firm lists GPN Vaccines on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

health care vaccine efficacy biotechnology research global health solutions manufacturing vaccine pipeline medical research immunological assessment multiserotype protection nonadjuvanted vaccines streptococcus pneumoniae clinical research hospital & health care immune response broad-spectrum vaccines medical

Built with from their website

Wistia Google Tag Manager WordPress.org Font Awesome CloudFlare Viewport Meta Babel CloudFlare CDN Priority Hints CAPTCHA

+8 more

Microsoft Exchange MySQL PrimeNG Microsoft 365 Apps & Services Mobile Friendly Open Graph jQuery RSS

- **Sector:** Research
- **Industry code:** NAICS 541714, 325414, SIC 2834
- **Region:** Australian Capital Territory
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/gpn-vaccines)

## Research in Australia

Startups like it

- [**PolyActiva** Melbourne · founded 2010 *Raised*](https://millionrounds.com/company/polyactiva)
- [**Ferronova** Adelaide · founded 2016 *Raised*](https://millionrounds.com/company/ferronova)
- [**Nbryo** Brisbane · founded 2020 *Raised*](https://millionrounds.com/company/nbryo)
- [**Fremantle Seaweed** Perth *Raised*](https://millionrounds.com/company/fremantle-seaweed)
- [**Bovotica** Brisbane · founded 2023 *Raised*](https://millionrounds.com/company/bovotica)
- [**Bower** Byron Bay · founded 2025 *Raised*](https://millionrounds.com/company/bower)
- [**Levur** Sydney · founded 2023 *Raised*](https://millionrounds.com/company/levur)
- [**Cell Bauhaus** Melbourne · founded 2023 *Raised*](https://millionrounds.com/company/cell-bauhaus)

## Is this your company?

Add your raise, your deck and your story, and put GPN Vaccines in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)